Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Mike Ankley who wrote (1017)	11/5/1998 5:15:00 PM
From: NASDBULL	Read Replies (1) \| Respond to of 3576

All the action on GERN is over on this thread! Message 6306544

To: Mike Ankley who wrote (1017)	11/5/1998 6:50:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3576

I worked with F9 ES cells as early as 1978, and I've followed stem cell work closely ever since. At the very top of this article, there is a diagram that says "in theory". Just a FYI for anyone that might want to avoid an "ENMD" tomorrow morning. Tom Okarma, for those who don't know it, is one of biotech's proven managers, having steered AIS to health through the sector's toughest funding period and to eventual purchase by Rhone Poulenc. If you're interested in transplantation and other potential applications of stem cells, check out Stem Cell Sciences Pty Ltd. The human stem cell is big stuff, but...... to take some of the Star Wars touch off of this.... people have been observing erythrocyte formation and muscle cell differentiation in ES cultures for well over 20 years.